GSK, CureVac to Make COVID-19 Vaccines Aimed at New Variants

Virus Outbreak Germany Vaccine

The logo of the biotech company Curevac with the slogan “the RNA people” (Sebastian Gollnow/dpa via AP)

LONDON (AP) – U.K.-based drugmaker GlaxoSmithKline and Germany’s CureVac say they plan to collaborate to develop new vaccines that can target emerging variants of COVID-19. The announcement comes as public health experts around the world raise concerns about mutations in the virus that may make existing vaccines less effective. The companies said in a statement Wednesday that “the increase in emerging variants with the potential to reduce the efficacy of first generation COVID-19 vaccines requires acceleration of efforts to develop vaccines against new variants to keep one step ahead of the pandemic.”

All contents © copyright 2021 Associated Press. All rights reserved

Categories: Coronavirus